Moleculin Biotech, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MBRX Nasdaq 2836 moleculin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Moleculin Biotech, Inc.

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - Jan 12th, 2026 6:36 am
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors - Dec 17th, 2025 6:31 am
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds - Dec 10th, 2025 6:30 am
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 - Dec 9th, 2025 6:07 am
Moleculin Announces New Annamycin Collaboration in Brain Tumors - Dec 8th, 2025 6:21 am
Moleculin to Participate in the Virtual Investor Closing Bell Series - Nov 26th, 2025 7:15 am
Moleculin Announces Reverse Stock Split - Nov 26th, 2025 7:00 am
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented - Nov 13th, 2025 6:36 am
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill - Nov 12th, 2025 6:37 am
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting - Oct 30th, 2025 6:40 am
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin - Oct 29th, 2025 6:35 am
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer - Oct 23rd, 2025 6:00 am
Moleculin Biotech announces issuance of Canadian patent covering Annamycin - Sep 26th, 2025 6:45 am
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin - Sep 25th, 2025 6:35 am
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know - Sep 17th, 2025 10:00 am
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial - Sep 9th, 2025 6:45 am
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - Sep 8th, 2025 6:30 am
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds - Aug 28th, 2025 6:30 am
Moleculin Issues New Positive AML Overall Survival Data: - Aug 27th, 2025 6:45 am
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 - Aug 15th, 2025 8:00 am